Douglas P. Calvin

1.4k total citations · 1 hit paper
12 papers, 1.1k citations indexed

About

Douglas P. Calvin is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Douglas P. Calvin has authored 12 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Douglas P. Calvin's work include Endometrial and Cervical Cancer Treatments (2 papers), Angiogenesis and VEGF in Cancer (2 papers) and Effects of Radiation Exposure (2 papers). Douglas P. Calvin is often cited by papers focused on Endometrial and Cervical Cancer Treatments (2 papers), Angiogenesis and VEGF in Cancer (2 papers) and Effects of Radiation Exposure (2 papers). Douglas P. Calvin collaborates with scholars based in United States, Netherlands and Germany. Douglas P. Calvin's co-authors include Rabih M. Salloum, Helena J. Mauceri, Michael A. Beckett, Donald Küfe, Nora Jaskowiak, Saraswathy Seetharam, Danielle M. Hari, Ann Koons, Ralph R. Weichselbaum and David H. Gorski and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Cancer and Metastasis Reviews.

In The Last Decade

Douglas P. Calvin

12 papers receiving 1.1k citations

Hit Papers

Blockage of the vascular endothelial growth factor stress... 1999 2026 2008 2017 1999 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    1999 723 citations David H. Gorski, Michael A. Beckett et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas P. Calvin United States 7 548 433 396 315 180 12 1.1k
Rumi Murata Japan 18 313 0.6× 356 0.8× 175 0.4× 349 1.1× 311 1.7× 33 966
Rajiv Bassi United States 19 925 1.7× 280 0.6× 783 2.0× 373 1.2× 288 1.6× 26 1.7k
Leonardo Faoro United States 16 686 1.3× 192 0.4× 691 1.7× 344 1.1× 70 0.4× 36 1.6k
Sergi Benavente Spain 15 523 1.0× 190 0.4× 931 2.4× 545 1.7× 207 1.1× 33 1.4k
Mio Li Japan 12 491 0.9× 271 0.6× 274 0.7× 341 1.1× 171 0.9× 19 982
S. Vignati Italy 15 879 1.6× 388 0.9× 793 2.0× 569 1.8× 116 0.6× 22 1.6k
Yozo Kawano Japan 19 657 1.2× 362 0.8× 435 1.1× 331 1.1× 93 0.5× 28 1.2k
Raija Ristamäki Finland 21 535 1.0× 307 0.7× 760 1.9× 230 0.7× 62 0.3× 52 1.3k
K. D. Danenberg United States 15 1.1k 1.9× 422 1.0× 825 2.1× 555 1.8× 127 0.7× 41 1.8k
A. Ramaioli France 17 402 0.7× 310 0.7× 800 2.0× 536 1.7× 98 0.5× 32 1.5k

Countries citing papers authored by Douglas P. Calvin

Since Specialization
Citations

This map shows the geographic impact of Douglas P. Calvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas P. Calvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas P. Calvin more than expected).

Fields of papers citing papers by Douglas P. Calvin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas P. Calvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas P. Calvin. The network helps show where Douglas P. Calvin may publish in the future.

Co-authorship network of co-authors of Douglas P. Calvin

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas P. Calvin. A scholar is included among the top collaborators of Douglas P. Calvin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas P. Calvin. Douglas P. Calvin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Eschrich, Steven A., Jimmy Pramana, Hongling Zhang, et al.. (2009). A Gene Expression Model of Intrinsic Tumor Radiosensitivity: Prediction of Response and Prognosis After Chemoradiation. International Journal of Radiation Oncology*Biology*Physics. 75(2). 489–496. 232 indexed citations
2.
Calvin, Douglas P., Thomas F. Pajak, Andy Trotti, et al.. (2007). Microvessel Density ≥60 Does Not Predict for Outcome After Radiation Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma. American Journal of Clinical Oncology. 30(4). 406–419. 11 indexed citations
3.
Leong, Stanley P. L., Blake Cady, David M. Jablons, et al.. (2006). Clinical patterns of metastasis. Cancer and Metastasis Reviews. 25(2). 221–232. 93 indexed citations
4.
Sekharam, Madhavi, et al.. (2005). CPA7, a Novel Stat3 Inhibitor Radiosensitizes Prostate Cancer Cells. International Journal of Radiation Oncology*Biology*Physics. 63. S483–S483. 1 indexed citations
5.
Yeatman, T., Caio M. Rocha Lima, James S. Barthel, et al.. (2004). Phase I trial of oral topotecan (OT) and radiotherapy (XRT) in rectal cancer (RCA). Journal of Clinical Oncology. 22(14_suppl). 3743–3743. 1 indexed citations
6.
Calvin, Douglas P., et al.. (2003). Inhibition of STAT3 activity with STAT3 antisense oligonucleotide (STAT3-ASO) enhances radiation-induced apoptosis in DU145 prostate cancer cells. International Journal of Radiation Oncology*Biology*Physics. 57(2). S297–S297. 15 indexed citations
7.
Grdina, David J., Jeffrey S. Murley, Yasushi Kataoka, & Douglas P. Calvin. (2002). Differential activation of nuclear transcription factor κB, gene expression, and proteins by amifostine's free thiol in human microvascular endothelial and glioma cells. Seminars in Radiation Oncology. 12(1). 103–111. 26 indexed citations
8.
Calvin, Douglas P., M. Elizabeth H. Hammond, Thomas F. Pajak, et al.. (2001). Microvessel density (mvd)≥60 does not predict for outcome in advanced head and neck squamous cell carcinoma (HNSCC): results of a prospective study from the RTOG 90-03 trial. International Journal of Radiation Oncology*Biology*Physics. 51(3). 41–41. 1 indexed citations
9.
Blend, Michael J., et al.. (2000). Use of ProstaScin®-CT image registration in the post-operative radiation therapy of prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 48(3). 358–359. 2 indexed citations
10.
Calvin, Douglas P., Philip P. Connell, Jacob Rotmensch, Steve Waggoner, & Arno J. Mundt. (1999). Surgery and Postoperative Radiation Therapy in Stage II Endometrial Carcinoma. American Journal of Clinical Oncology. 22(4). 338–343. 25 indexed citations
11.
Gorski, David H., Michael A. Beckett, Nora Jaskowiak, et al.. (1999). Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.. PubMed. 59(14). 3374–8. 723 indexed citations breakdown →
12.
Calvin, Douglas P., Philip P. Connell, Patrick J. Sweeney, et al.. (1997). 2112 Prognostic factors and patterns of failure in pathologic stage II endometrial cancer. International Journal of Radiation Oncology*Biology*Physics. 39(2). 296–296. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rumi Murata Breakdown of academic impact, for papers by Rajiv Bassi Breakdown of academic impact, for papers by Leonardo Faoro Breakdown of academic impact, for papers by Sergi Benavente Breakdown of academic impact, for papers by Mio Li Breakdown of academic impact, for papers by S. Vignati Breakdown of academic impact, for papers by Yozo Kawano Breakdown of academic impact, for papers by Raija Ristamäki Breakdown of academic impact, for papers by K. D. Danenberg Breakdown of academic impact, for papers by A. Ramaioli
Rankless by CCL
2026